Vaccines Market Size, Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated), By Route of Administration (Parenteral & Oral), By Disease Indication (Viral Diseases (Hepatitis, Influenza, Human Papillomavirus) and Bacterial Diseases (Meningococcal, Pneumococcal)), By Age Group (Pediatric & Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers) & Region Forecast, 2021-2026 (Includes COVID-19 Business Impact)

                                          
A mainstay of preventative medicine for over 70 years, a vaccine is a biological preparation used to trigger an immune response to a selected disease. As a result of widespread public vaccination, vaccine-preventable diseases and their resulting deaths are now rare in the developed nations and declining worldwide. Immunizations have eradicated smallpox; eliminated poliomyelitis in the Americas; and controlled measles, rubella, tetanus, diphtheria, Haemophilus influenza type b, and other infectious diseases. Vaccination risks range from common, minor, and local adverse effects to rare, severe, and life-threatening conditions. For example, some autoimmune diseases like acute disseminated encephalomyelitis, Guillain-Barré syndrome, transverse myelitis, and multiple sclerosis are known to be connected to vaccines. In addition, some studies have linked a significant rise in autism to certain vaccines, although there is no widespread agreement on this. Thus, recommendations for immunization practices balance scientific evidence of benefits for each person and to society against the potential costs and risks of vaccination programs. These risks, however, have led to a rising number of individuals declining vaccination for themselves and their children, which in turn is believed to have contributed to recent increases in several serious, highly infectious conditions including mumps. The European market is presently the second-largest global vaccine market, with nearly 23% of the market. 

In 2020, the global market for human preventive vaccines experienced mixed performance in 2020 due to the impact of COVID-19. Sales overall declined in 2020. Though some segments reported increases in sales volume, viz., Influenza vaccines, Rotavirus vaccines, and Shingles vaccines.

Through the forecast period 2021-2026, growth will be fueled by favorable demographics (population growth, rising life expectancy), continued new product introductions, indication expansions for some products, and rising usage, particularly in India and China. However, mitigating against growth will be continuing concerns about vaccine safety and refusal to immunize. 

We have updated Vaccines Market with respect to COVID-19 Business Impact.
Inquire before buying

This report focuses on the Vaccines market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Vaccines market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Vaccines Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Vaccines Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Vaccines Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

GSK, Sanofi, Pfizer, and Merck Together Rule the Vaccines Market
The vaccines market is dominated by large vaccine suppliers across the globe. The top market players, such as GlaxoSmithKline plc., Sanofi, Pfizer Inc. and Merck & Co., Inc., account for the majority of the market. These companies have a strong product portfolio, the capability of strategic decisions and focus on resolving the unmet needs in eradicating complex diseases through vaccination. Constant exhaustive R&D resulting in approvals and launches of vaccines worldwide is expected to maintain their position in the vaccines market. Increasing demand for vaccine doses for viral as well as bacterial diseases is anticipated to fuel the company growth and market value in the human vaccines manufacturing industry.

List Of key Companies Covered:

 	
GlaxoSmithKline plc.
 	
Sanofi
 	
Pfizer Inc.
 	
Merck & Co., Inc.
 	
Novartis AG
 	
Emergent BioSolutions, Inc.
 	
CSL Limited
 	
Inovio Pharmaceuticals, Inc.
 	
Bavarian Nordic
 	
Mitsubishi Tanabe Pharma Corporation.
 	
Other Prominent Players

REPORT COVERAGE

Secure government support, growing endemic diseases, and rising demand for vaccination doses are the factors responsible for remarkable growth in the vaccination market during the forecast period. This, in turn, is expected to pressurize companies for manufacturing and distributing large vaccine doses in every corner of the world.
Along with this, the report provides detailed information regarding various insights into the market. Some of them are growth drivers, restraints, competitive landscape, regional analysis, and challenges. It further offers an analytical depiction of the vaccine market trends and estimations to illustrate the forthcoming investment pockets. The market is quantitatively analyzed from 2019 to 2026 to provide the financial competency of the market. The information gathered in the report has been taken from several primary and secondary sources.

Report Scope & Segmentation

 Segmentation

By Type

 	
Recombinant/Conjugate/Subunit
 	
Inactivated
 	
Live Attenuated
 	
Toxoid

By Route of Administration

 	
Parenteral
 	
Oral

By Disease Indication

Viral Diseases

 	
Hepatitis
 	
Influenza
 	
Human Papillomavirus
 	
Measles/Mumps/Rubella
 	
Rotavirus
 	
Herpes Zoster
 	
Others

Bacterial Diseases

 	
Meningococcal Disease
 	
Pneumococcal Disease
 	
Diphtheria/Tetanus/Pertussis
 	
Others

By Age Group

 	
Pediatric
 	
Adults

By Distribution Channel

 	
Hospital & Retail Pharmacies
 	
Government Suppliers
 	
Others

By Geography

 	
North America (U.S. and Canada)
 	
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
 	
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
 	
Latin America (Brazil, Mexico, and Rest of Latin America)
 	
Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

INDUSTRY DEVELOPMENT:

In August 2020, MYR GmbH received marketing authorization valid throughout the European Union for Hepcludex(Bulevirtide) which is an antiviral medicine used to treat chronic (long-term) hepatitis delta virus (HDV) infection in adults with compensated liver disease (when the liver is damaged but is still able to work), when the presence of viral RNA (genetic material) has been confirmed by blood tests. HDV is an 'incomplete' virus, because it cannot replicate in cells without the help of another virus, the hepatitis B virus. Because of this, patients infected with the virus always also have hepatitis B. Hepcludex can be given on its own, or in combination with a ‘nucleoside/nucleotide analogue’ medicine for the treatment of the underlying hepatitis B infection.
The active substance in Hepcludex, bulevirtide, works by attaching to and blocking a receptor (target) through which the hepatitis delta and hepatitis B viruses enter liver cells. By blocking the entry of the virus into the cells, Hepcludex limits the ability of HDV to replicate and its effects in the body, reducing symptoms of the disease.
HDV infection is rare, and Hepcludex was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 June 2015. MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D.

September 2019: Kenya joined Ghana and Malawi by launching the worlds first malaria vaccines. The malaria vaccines pilot program is fully underway as malaria affects millions of people in Africa.

April 2019: World Health Organization (WHO) welcomed the worlds first malaria vaccines by the government of Malawis landmark pilot program which was launched in Africa.

May 2019: Sanofi Pasteur received USFDA green signal for its dengue fever vaccines DENGVAXIA for launch in the U.S.

January 2019: Vaccines market giants Sanofi and Merck received USFDA approval for its six-in-one pediatric vaccines VAXELIS. The vaccines are indicated against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, and Haemophilus influenza type b.